CommunicationsCaitlin Kasunich+1 212 896 1241 [[email protected]]SOURCE Immunic, Inc.## 21%[more press release views with Request a Demo]## Also from this source### Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update[Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and...]### Immunic Announces Closing of Oversubscribed Private Placement Financing[Immunic, Inc. (Nasdaq: IMUX), a late-stage biotec ...